PT1272507E - Derivados de peptidos para ligacao a integrina - Google Patents

Derivados de peptidos para ligacao a integrina

Info

Publication number
PT1272507E
PT1272507E PT01924011T PT01924011T PT1272507E PT 1272507 E PT1272507 E PT 1272507E PT 01924011 T PT01924011 T PT 01924011T PT 01924011 T PT01924011 T PT 01924011T PT 1272507 E PT1272507 E PT 1272507E
Authority
PT
Portugal
Prior art keywords
integrina
peptides
derivatives
connection
agents
Prior art date
Application number
PT01924011T
Other languages
English (en)
Portuguese (pt)
Inventor
Cuthbertson Alan
Indrevoll Bard
Original Assignee
Amersham Health As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0009042A external-priority patent/GB0009042D0/en
Priority claimed from GB0025070A external-priority patent/GB0025070D0/en
Application filed by Amersham Health As filed Critical Amersham Health As
Publication of PT1272507E publication Critical patent/PT1272507E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT01924011T 2000-04-12 2001-04-06 Derivados de peptidos para ligacao a integrina PT1272507E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0009042A GB0009042D0 (en) 2000-04-12 2000-04-12 Contrast agents
GB0025070A GB0025070D0 (en) 2000-10-12 2000-10-12 Contrast agents

Publications (1)

Publication Number Publication Date
PT1272507E true PT1272507E (pt) 2005-11-30

Family

ID=26244091

Family Applications (1)

Application Number Title Priority Date Filing Date
PT01924011T PT1272507E (pt) 2000-04-12 2001-04-06 Derivados de peptidos para ligacao a integrina

Country Status (16)

Country Link
US (2) US7351790B2 (enExample)
EP (1) EP1272507B1 (enExample)
JP (1) JP5043271B2 (enExample)
KR (2) KR100879702B1 (enExample)
CN (1) CN1230441C (enExample)
AT (1) ATE298763T1 (enExample)
AU (2) AU2001250683B2 (enExample)
CA (1) CA2405469C (enExample)
DE (1) DE60111733T2 (enExample)
DK (1) DK1272507T3 (enExample)
ES (1) ES2244607T3 (enExample)
HK (1) HK1052711A1 (enExample)
NO (1) NO331741B1 (enExample)
NZ (1) NZ521735A (enExample)
PT (1) PT1272507E (enExample)
WO (1) WO2001077145A2 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7452551B1 (en) 2000-10-30 2008-11-18 Imarx Therapeutics, Inc. Targeted compositions for diagnostic and therapeutic use
NZ521735A (en) * 2000-04-12 2004-12-24 Amersham Health As Peptide-based compounds, their use as targeting vectors that bind to receptors associated with antiogenesis such as integrin receptors
NO20004795D0 (no) * 2000-09-26 2000-09-26 Nycomed Imaging As Peptidbaserte forbindelser
JP4510444B2 (ja) * 2001-07-10 2010-07-21 ジーイー・ヘルスケア・アクスイェ・セルスカプ ペプチドベースの化合物
EP1575496A4 (en) * 2002-04-05 2008-01-23 Univ Utah Res Found COLON TUMOR SPECIFIC BINDING PEPTIDES
CN100491395C (zh) * 2002-04-11 2009-05-27 阿斯比奥制药株式会社 修饰肽的制造方法
GB0224799D0 (en) * 2002-10-25 2002-12-04 Amersham Plc Improved complex compositions
NO20030115D0 (no) 2003-01-09 2003-01-09 Amersham Health As Kontrastmiddel
NO20033115D0 (no) 2003-07-08 2003-07-08 Amersham Health As Peptid-baserte forbindelser
GB0317815D0 (en) 2003-07-30 2003-09-03 Amersham Health As Imaging agents
JP2007526300A (ja) 2004-03-04 2007-09-13 ジーイー・ヘルスケア・アクスイェ・セルスカプ 医薬化合物
CN1968963A (zh) * 2004-06-16 2007-05-23 通用电气医疗集团股份有限公司 基于肽的化合物
JP5280682B2 (ja) * 2004-06-16 2013-09-04 ジーイー・ヘルスケア・アクスイェ・セルスカプ ペプチド系化合物
EP1765172B1 (en) * 2004-06-18 2013-04-24 Elmaleh, David R. Intravascular imaging device and uses thereof
RU2007118385A (ru) * 2004-11-22 2008-12-27 Джи-И Хелткер АС (NO) Контрастные агенты для направлений доставки во внеклеточный матрикс
GB0428012D0 (en) * 2004-12-22 2005-01-26 Hammersmith Imanet Ltd Radiolabelling methods
WO2006073314A1 (en) * 2005-01-06 2006-07-13 Ge Healthcare As Optical imaging
CA2625196C (fr) 2005-10-07 2016-04-05 Guerbet Composes comprenant une partie de reconnaissance d'une cible biologique, couplee a une partie de signal capable de complexer le gallium
US8986650B2 (en) 2005-10-07 2015-03-24 Guerbet Complex folate-NOTA-Ga68
JP2010502585A (ja) * 2006-08-28 2010-01-28 ジーイー・ヘルスケア・リミテッド ６８Ｇａ標識ペプチド系放射性医薬品
CN102321154A (zh) * 2006-12-11 2012-01-18 通用电气医疗集团股份有限公司 基于放射性标记的肽的化合物及其用途
US20090004119A1 (en) * 2007-06-27 2009-01-01 Ge Healthcare As Polymers
DE102007036570A1 (de) 2007-08-03 2009-02-19 Siemens Ag Screeningtest zur Erkennung von Prostataerkrankungen sowie Vorrichtung und Diagnosesubstanz zur Durchführung des Tests
US20100178245A1 (en) * 2009-01-13 2010-07-15 Arnsdorf Morton F Biocompatible Microbubbles to Deliver Radioactive Compounds to Tumors, Atherosclerotic Plaques, Joints and Other Targeted Sites
FR2942227B1 (fr) 2009-02-13 2011-04-15 Guerbet Sa Utilisation de tampons pour la complexation de radionucleides
FR2968999B1 (fr) 2010-12-20 2013-01-04 Guerbet Sa Nanoemulsion de chelate pour irm
FR2980364B1 (fr) 2011-09-26 2018-08-31 Guerbet Nanoemulsions et leur utilisation comme agents de contraste
FR3001154B1 (fr) 2013-01-23 2015-06-26 Guerbet Sa Magneto-emulsion vectorisee
EP3365353B1 (en) * 2015-10-23 2023-11-22 Universiteit Twente Integrin binding peptides and uses thereof
WO2019040367A1 (en) * 2017-08-19 2019-02-28 Ohio State Innovation Foundation NEW CANCER IMAGING AGENTS BASED ON PEPTIDES
WO2020007822A1 (en) 2018-07-02 2020-01-09 Conservatoire National Des Arts Et Metiers (Cnam) Bismuth metallic (0) nanoparticles, process of manufacturing and uses thereof
EP3970801A4 (en) * 2019-05-14 2022-11-02 Ichimaru Pharcos Co., Ltd. RAS INHIBITOR PEPTIDE

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4647447A (en) 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
DE3869251D1 (de) 1987-07-16 1992-04-23 Nycomed As Aminopolycarbonsaeure und ihre derivate.
US5753627A (en) * 1988-12-05 1998-05-19 Novartis Ag Use of certain complexed somatostatin peptides for the invivo imaging of somatostatin receptor-positive tumors and metastasis
US5364613A (en) 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
IE901736L (en) 1989-05-17 1990-11-17 Fuller H B Licensing Financ Polypeptide-antibody conjugate for inhibiting cell adhesion
US5367080A (en) 1990-11-08 1994-11-22 Sterling Winthrop Inc. Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods
UA43823C2 (uk) 1992-07-06 2002-01-15 Мерк Патент Геселлшафт Міт Бесшренктер Хафтунг ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ДЛЯ ІНГІБУВАННЯ ІНТЕГРИН <font face="Symbol">a</font><sub>V</sub><font face="Symbol">b</font><sub>3</sub>-ОПОСЕРЕДКОВАНОЇ КЛІТИННОЇ АДГЕЗІЇ КЛІТИН ССАВЦІВ, СПОСІБ ЛІКУВАННЯ ТА ПРОФІЛАКТИКИ ЗАХВОРЮВАННЯ, АСОЦІЙОВАНОГО З ПОРУШЕННЯМ АДГЕЗІЇ КЛІТИН, СПОСІБ БЛОКУВАННЯ ЗВ'ЯЗУВАННЯ ФІБРИНОГЕНОМ ІНТЕГРИНУ, КОМПОЗИЦІЯ ДЛЯ ЗАГОЄННЯ РАН
US5981478A (en) * 1993-11-24 1999-11-09 La Jolla Cancer Research Foundation Integrin-binding peptides
US5753230A (en) 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
IL113139A0 (en) 1994-03-28 1995-06-29 Nycomed Imaging As Diagnostic compositions comprising imaging agents encapsulated in liposomes
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
GB9420390D0 (en) 1994-10-10 1994-11-23 Nycomed Salutar Inc Liposomal agents
AU726793B2 (en) 1995-08-14 2000-11-23 Scripps Research Institute, The Methods and compositions useful for inhibition of alpha v beta 5 mediated angiogenesis
ES2299232T3 (es) 1995-09-11 2008-05-16 La Jolla Cancer Research Foundation Moleculas que migran hacia un organo o tejido seleccionado in vivo.
JP4280304B2 (ja) 1996-01-10 2009-06-17 ジーイー・ヘルスケア・アクスイェ・セルスカプ 造影剤
WO1997028830A1 (de) 1996-02-09 1997-08-14 Steinel Gmbh & Co. Kg Vorrichtung zum verdunsten eines flüssigen wirkstoffes
JP2001501600A (ja) 1996-09-10 2001-02-06 ザ バーナム インスティテュート 腫瘍ホーミング分子、それに由来する結合体、およびその使用方法
GB9708265D0 (en) * 1997-04-24 1997-06-18 Nycomed Imaging As Contrast agents
CA2291323A1 (en) 1997-05-28 1998-12-03 Genvec, Inc. Alternatively targeted adenovirus
GB9711115D0 (en) 1997-05-29 1997-07-23 Inst Of Child Health Integrin-targeting vectors having enhanced transfection activity
EP1053013A4 (en) 1998-02-06 2004-12-22 Uab Research Foundation ADENOVIRUS VECTOR CONTAINING A HETEROLOGICAL PEPTIDEPITOP IN THE HI LOOP OF THE FIBER BUTTON
AU2662999A (en) 1998-02-09 1999-08-23 Genzyme Corporation Nucleic acid delivery vehicles
NZ521735A (en) * 2000-04-12 2004-12-24 Amersham Health As Peptide-based compounds, their use as targeting vectors that bind to receptors associated with antiogenesis such as integrin receptors
NO20033115D0 (no) * 2003-07-08 2003-07-08 Amersham Health As Peptid-baserte forbindelser

Also Published As

Publication number Publication date
AU5068301A (en) 2001-10-23
ATE298763T1 (de) 2005-07-15
US7351790B2 (en) 2008-04-01
CN1230441C (zh) 2005-12-07
AU2001250683B2 (en) 2006-06-29
EP1272507B1 (en) 2005-06-29
DK1272507T3 (da) 2005-10-03
NO20024932D0 (no) 2002-10-14
KR20080036662A (ko) 2008-04-28
CA2405469A1 (en) 2001-10-18
NZ521735A (en) 2004-12-24
CA2405469C (en) 2012-03-20
KR100866666B1 (ko) 2008-11-04
US8404802B2 (en) 2013-03-26
DE60111733T2 (de) 2006-05-18
DE60111733D1 (de) 2005-08-04
HK1052711A1 (zh) 2003-09-26
JP5043271B2 (ja) 2012-10-10
KR20020087973A (ko) 2002-11-23
NO331741B1 (no) 2012-03-19
US20080187493A1 (en) 2008-08-07
EP1272507A2 (en) 2003-01-08
WO2001077145A3 (en) 2002-05-10
ES2244607T3 (es) 2005-12-16
KR100879702B1 (ko) 2009-01-21
US20030204049A1 (en) 2003-10-30
WO2001077145A2 (en) 2001-10-18
CN1436195A (zh) 2003-08-13
JP2003531835A (ja) 2003-10-28

Similar Documents

Publication Publication Date Title
PT1272507E (pt) Derivados de peptidos para ligacao a integrina
MXPA04000173A (es) Compuestos basados en peptidos.
ATE442379T1 (de) Bildgebende agentien auf basis bizyklischer peptide
BG66085B1 (bg) Фенилаланинови производни
CY1113003T1 (el) Ευσταθη παρασκευασματα laquinimod
MA31231B1 (fr) Anticorps anti-robo4 et utilisations de ceux-ci
MA28843B1 (fr) Therapie d&#39;association utilisant des proteines de fusion de trasferrine comprenant glp-1
ATE404225T1 (de) Radiofluorierte peptide
BR0313420A (pt) Quinolonas microbicidas, suas composições e usos
NO20032208D0 (no) Benzodiazepinderivater som GABA A reseptormodulatorer
CR10842A (es) Derivados de acetileno y su uso para la union a placas amiloides y su diagnostico por imagenes
BR0206595A (pt) Composto, composição farmacêutica, e uso de um composto
WO2006095234A3 (en) Integrin targeted synthetic ligands for diagnostic and therapeutic applications
ES2187261B2 (es) Compuestos de eteres y amidas y su preparacion, como agentes anti-diabeticos.
AU2002339007A1 (en) Preparation of cholecystokinin agonists and antagonists, and their therapeutic and diagnostic use
SE9901077D0 (sv) Novel use
BR0213684A (pt) Uso de antagonistas do receptor de endotelina para o tratamento de doenças tumorìgenas
WO2008026040A3 (en) 68ga-labeled peptide-based radiopharmaceuticals
EP1758605A4 (en) PROUROGUANYLIN AS THERAPEUTIC AND DIAGNOSTIC AGENTS
DE602004031617D1 (de) Fluoresceinmarkierte peptide
ATE425770T1 (de) Kontrastmittel
BRPI0414107B8 (pt) produtos intermediários para a preparação de híbridos de oxazolidinon-quinolona
ATE480552T1 (de) Stq-peptide
AR031126A1 (es) Acidos amino(oxo)aceticos inhibidores de la proteina tirosina fosfatasa
GT200600296A (es) Derivados de n-[(1,5-fenil-1h-pirazol-3-il)-metil] sulfonamida, su preparación y su aplicación en terapeutica